13 results found.

Congenital Bleeding Disorder, or Haemophilia A Clinical Trial using NNC 0129-0000-1003

Novo Nordisk - Recruiting 12 years or older.
- Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A.
NNC 0129-0000-1003

Hemophilia A Clinical Trial using BAY94-9027

Bayer - Recruiting N/A to 12 years.
- A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A.
BAY94-9027

Hemophilia A Clinical Trial using Biostate

CSL Behring - Recruiting N/A to 11 years.
- A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostater) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (ó 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors).
Biostate

Haemophilia A Clinical Trial using Recombinant Factor VIII (BAY81-8973)

Bayer - Recruiting N/A to 12 years.
- A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy.
Recombinant Factor VIII (BAY81-8973)

Congenital Bleeding Disorder, or Haemophilia A Clinical Trial using NNC 0129-0000-1003

Novo Nordisk - Recruiting N/A to 11 years.
- A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A.
NNC 0129-0000-1003

Congenital Bleeding Disorder, or Haemophilia A Clinical Trial using turoctocog alfa

Novo Nordisk - Recruiting N/A to 5 years.
- Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A.
turoctocog alfa

Hemophilia Clinical Trial using Recombinant Factor VIII (Kogenate, BAY14-2222)

Bayer - Recruiting 18 years or older.
- Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis.
Recombinant Factor VIII (Kogenate, BAY14-2222)

Severe Haemophilia A Clinical Trial using Human-cl rhFVIII

Octapharma - Recruiting 18 years or older.
- Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A.
Human-cl rhFVIII

Hemophilia A Clinical Trial using GreenGeneT F and an approved recombinant Factor VIII product; GreenGeneT F

Green Cross Corporation - Recruiting 12 years or older.
- Determination of Safety, Efficacy and Pharmacokinetics of GreenGeneT F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A.
GreenGeneT F and an approved recombinant Factor VIII product; GreenGeneT F

Hemophilia B Clinical Trial using rIX-FP

CSL Behring - Recruiting N/A to 11 years.
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B.
rIX-FP

Acquired Haemophilia Clinical Trial using Steroid + cyclophosphamide; Steroid + rituximab

University Hospital, Rouen - Recruiting 18 years or older.
- Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study).
Steroid + cyclophosphamide; Steroid + rituximab